MDACC Study No:2009-0759 ( NCT No: NCT01113463)
Title:A Phase 2 Open-Label Study of the Efficacy of TPI 287 in Patients with Glioblastoma Multiforme That Has Recurred or Progressed Following Prior Therapy with Radiation plus Temozolomide
Principal Investigator:Charles A. Conrad
Treatment Agent:TPI 287
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if TPI 287 can help to
control glioblastoma. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase II
Treatment Agents:TPI 287
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:Archer Biosciences, Inc
Return Visit:Every 3 weeks
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Charles A. Conrad
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults